ICU Medical, Inc. — Q2 2012 Form 10-Q
Reporting period: Three and six months ended June 30, 2012. Unless otherwise indicated, financial amounts below are in millions of dollars. The company develops and sells medical devices for infusion therapy, critical care, and oncology.
Financial performance
| Metric | Q2 2012 | Q2 2011 | H1 2012 | H1 2011 |
|---|---|---|---|---|
| Total revenue | $77.3 | $77.8 | $152.8 | $149.3 |
| Gross profit / margin | $39.1 / 51% | $36.2 / 47% | $74.0 / 48% | $70.8 / 47% |
| Operating income / margin | $13.5 / 18% | $14.0 / 18% | $24.9 / 16% | $26.2 / 18% |
| Net income | $9.1 | $9.5 | $16.8 | $17.6 |
| Diluted earnings per share | $0.63 | $0.67 | $1.16 | $1.24 |
| Operating cash flow | Not separately reported | Not separately reported | $31.5 | $25.5 |
- Q2 revenue was down 0.7% year over year; H1 revenue rose 2.4%. Q2 gross margin improved four percentage points, while operating income and net income declined.
- For H1, infusion therapy sales increased 7% to $102.4 million and oncology sales increased 10% to $13.5 million. Critical care sales fell 10% to $29.4 million; other product sales declined 13% to $7.2 million.
- H1 operating cash flow increased to $31.5 million. Investing activities used $21.7 million, including $8.2 million for property and equipment; financing activities provided $13.2 million.
- Cash, cash equivalents, and investment securities totaled $193.5 million at June 30, up from $160.0 million at year-end 2011. Current assets were $293.4 million and current liabilities $29.8 million. The balance sheet lists no borrowings or debt line item.
- Total assets were $392.6 million and stockholders’ equity $351.5 million. The company held $71.9 million of investment securities, classified as available-for-sale and investment grade.
Material changes and management commentary
- Domestic sales increased 5% in Q2, while international sales fell 14% to $20.7 million. Management attributed international weakness to Europe’s soft economy and currency effects; the weaker euro reduced Q2 international sales by an estimated $1.3 million and H1 sales by $1.8 million.
- Q2 gross-margin improvement reflected favorable Mexican peso exchange rates, product mix, and manufacturing efficiencies. Management said the peso effect contributed more than one percentage point to the Q2 margin increase.
- H1 operating income decreased despite higher gross profit. The 2011 comparison included a $2.5 million legal-settlement credit in operating expenses; 2011 SG&A also included a $2.0 million one-time long-term retention plan expense.
- Hospira accounted for 38% of Q2 revenue and 40% of H1 revenue. It represented 27% of accounts receivable at June 30. The filing emphasizes that the relationship remains important to sales and growth.
Outlook, risks, and unusual items
- Management expected 2012 capital expenditures of approximately $13 million to $18 million, SG&A of approximately 27% of revenue, R&D of approximately 3.3% of revenue, and an effective tax rate of approximately 34%. These are estimates, not assurances.
- Management anticipated modest 2012 growth in infusion therapy and other domestic sales, significant oncology growth, and lower critical care sales. It cited pricing reductions and competition in critical care; increased competition also pressured certain critical-care prices.
- The company said current cash, investments, and expected operating cash generation should fund operations for the next twelve months. It had $28.1 million remaining under its $40 million share-repurchase authorization and made no repurchases in Q2 or H1 2012.
- Key exposures include customer concentration, potential changes in Hospira’s business or market position, competition, product-development and commercialization risk, European economic and foreign-exchange weakness, manufacturing costs, and customer ordering fluctuations. The company does not hedge its foreign-currency exposures.
- ICU Medical continued patent litigation against RyMed. A jury had found infringement and the patents valid; a post-trial issue remained pending, after which a further trial was expected to determine damages, if any. Management stated other routine legal matters were not expected to have a material adverse effect.
- Indemnification agreements have no stated maximum exposure, though management reported no prior liability and did not expect a material liability. Contractual obligations totaled $15.4 million, primarily purchase obligations due in 2012.
Most important facts for investors to verify
- Whether Hospira concentration, contract terms, or sales patterns change materially.
- Whether infusion and oncology growth can offset critical-care declines and international weakness.
- Whether improved gross margins persist after favorable currency and manufacturing effects.
- Actual 2012 capital spending, expense ratios, tax rate, and cash generation versus management estimates.
- Developments and potential damages in the RyMed patent litigation, and any material change in contingencies or indemnification exposure.